Quent Capital’s Travere Therapeutics TVTX Stock Holding History

Quent Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-89	Closed	-$2K	–	1347
2023 Q1	$2K	Hold	89	–	–	﹤0.01%	1170
2022 Q4	$1.87K	Buy	+89	New	+$1.89K	﹤0.01%	1160

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Quent Capital's TVTX Position: Q2 2023 in Review

Quent Capital sold out of Travere Therapeutics (TVTX) in Q2 2023, closing a stake of 89 shares — an estimated $2K sold.

Quent Capital first reported a position in TVTX in Q4 2022 and held it in 2 quarters. The position peaked at $2K in Q1 2023. 169 funds tracked by Wall St. Rank hold TVTX as of Q2 2023.

Quent Capital reported no remaining Travere Therapeutics position as of Q2 2023 after selling out during the quarter.
Quent Capital sold 89 Travere Therapeutics shares in Q2 2023, an estimated $2K.
Quent Capital first reported a position in Travere Therapeutics in Q4 2022 and held it in 2 quarters.
Quent Capital's Travere Therapeutics position peaked at $2K in Q1 2023.
169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2023.

Based on Quent Capital's 13F filing for Q2 2023, filed 10 Jul 2023.